Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains controversial. We investigated the DAA treatment response in CHC patients with HCC. Methods: We retrospectively analyzed CHC patients treated with DAA from 2016 to 2018. Patients were divided into two groups based on their HCC-history before DAA therapy. Baseline characteristics, sustained virologic response at 12 weeks (SVR 12), and HCC recurrence after DAA therapy were evaluated. We also used propensity score matching (PSM) in a 2:1 ratio to reduce confounding variables. Results: A total of 192 patients were enrolled; 78.1% were treatment-naïve, and 34.9% had liver cirrhosis (LC). Among these patients, 168 did not have HCC, and 24 had HCC. The HCC group was older (57.0 years vs. 72.0 years, p < 0.001), had a higher incidence of LC (26.2% vs. 95.8%, p < 0.001), fibrosis-4 index (2.6 vs. 9.2, p < 0.001), liver stiffness measurement (7.0 kPa vs. 17.4 kPa, p = 0.012), and α-fetoprotein (4.4 ng/mL vs. 8.2 ng/mL, p ≤ 0.001). The SVR 12 rate was 97.0% in the non- HCC group and 91.7% in the HCC group (p = 0.213). HCC recurrence was observed in 14 patients (58.3%) in the HCC group. Conclusions: DAA treatment efficacy in CHC patients with or those without HCC were not significantly different, and HCC recurrence was relatively common.
Abstract
Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains controversial. We investigated the DAA treatment response in CHC patients with HCC. Methods: We retrospectively analyzed CHC patients treated with DAA from 2016 to 2018. Patients were divided into two groups based on their HCC-history before DAA therapy. Baseline characteristics, sustained virologic response at 12 weeks (SVR 12), and HCC recurrence after DAA therapy were evaluated. We also used propensity score matching (PSM) in a 2:1 ratio to reduce confounding variables. Results: A total of 192 patients were enrolled; 78.1% were treatment-naïve, and 34.9% had liver cirrhosis (LC). Among these patients, 168 did not have HCC, and 24 had HCC. The HCC group was older (57.0 years vs. 72.0 years, p < 0.001), had a higher incidence of LC (26.2% vs. 95.8%, p < 0.001), fibrosis-4 index (2.6 vs. 9.2, p < 0.001), liver stiffness measurement (7.0 kPa vs. 17.4 kPa, p = 0.012), and α-fetoprotein (4.4 ng/mL vs. 8.2 ng/mL, p ≤ 0.001). The SVR 12 rate was 97.0% in the non- HCC group and 91.7% in the HCC group (p = 0.213). HCC recurrence was observed in 14 patients (58.3%) in the HCC group. Conclusions: DAA treatment efficacy in CHC patients with or those without HCC were not significantly different, and HCC recurrence was relatively common.
참고문헌 (25)
- Polaris Observatory HCV Collaborators, "Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : a modelling study", Lancet Gastroenterol Hepatol, 2, pp.161~176 (2017)
- El-Serag HB, "Epidemiology of viral hepatitis and hepatocellular carcinoma", Gastroenterology, 142, pp.1264~1273 (2012)
- Foster GR, "Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis", J Hepatol, 64, pp.1224~1231 (2016)
- Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease", Gastroenterology, 149, pp.649~659 (2015)
- Manns M, "Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4hepatitis C virus infection and advanced liver disease : a multicentre, open-label, randomised, phase 2 trial", Lancet Infect Dis, 16, pp.685~697 (2016)
- Chung-Feng Huang, "Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?", Clinical and Molecular Hepatology, 25(2), pp.168~171 (2019), 대한간학회
- Beste LA, "Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma", J Hepatol, 67, pp.32~39 (2017)
- Shin HR, "Hepatitis B and C virus prevalence in a rural area of South Korea : the role of acupuncture", Br J Cancer, 87, pp.314~318 (2002)
- Reig M, "Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy", J Hepatol, 65, pp.719~726 (2016)
- Conti F, "Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals", J Hepatol, 65, pp.727~733 (2016)
- Ide T, "Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development : a prospective, multicenter study", Hepatol Int, 13, pp.293~301 (2019)
- Huang P, "The development of hepatocellular carcinoma in HCV-infected patients treated with DAA : a comprehensive analysis", Carcinogenesis, 39, pp.1497~1505 (2018)
- Waziry R, "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review, meta-analyses, and meta-regression", J Hepatol, 67, pp.1204~1212 (2017)
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Cheung MCM, "Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis", J Hepatol, 65, pp.741~747 (2016)
- Hsu YC, "Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma", Hepatology, 58, pp.150~157 (2013)
- Shirabe K, "Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma", Anticancer Res, 35, pp.6963~6969 (2015)
- Kanogawa N, "Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor", J Gastroenterol Hepatol, 30, pp.1197~1204 (2015)
- Guarino M, "Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection : literature review and risk analysis", Dig Liver Dis, 50, pp.1105~1114 (2018)
- Singh S, "Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma : a systematic review and meta-analysis", Frontline Gastroenterol, 9, pp.262~270 (2018)
- Yoshimasu Y, "Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C", J Gastrointestin Liver Dis, 28, pp.63~71 (2019)
- Pinero F, "Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma", Liver Int, 39, pp.1033~1043 (2019)
- Reig M, "Liver cancer emergence associated with antiviral treatment: an immune surveillance failure?", Semin Liver Dis, 37, pp.109~118 (2017)
- Ohki T, "Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients", Clin Gastroenterol Hepatol, 6, pp.459~464 (2008)